Twist Bioscience Expands Express Genes Rapid Synthesis Service
Portfolio Pulse from Benzinga Newsdesk
Twist Bioscience Corporation (NASDAQ:TWST) has expanded its Twist Express Genes service to include larger DNA preparations up to 1 milligram. The service, which offers a turnaround starting at five business days, now covers midiprep and maxiprep DNA preparations. This expansion enables researchers in various fields to access rapid gene synthesis at all scales, facilitating large scale experimentation and accelerating research and discoveries. Twist leverages its silicon-based DNA synthesis platform and the expanded layout of its Wilsonville facility to deliver these services with dynamic pricing.
January 24, 2024 | 1:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Twist Bioscience's expansion of its Express Genes service to include larger DNA preparations could attract more customers and potentially increase revenue. The service's rapid turnaround and scale may give TWST a competitive edge in the synthetic DNA market.
The expansion of the Express Genes service directly impacts Twist Bioscience's product offering, potentially increasing its market share and customer base in the synthetic DNA sector. The positive feedback from customers and the ability to cater to larger scale experiments are likely to be viewed favorably by investors, which could lead to a short-term positive impact on TWST's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100